Figure 7.

CRAd-S-pk7 NSCs Combination with Cisplatin (Orthotopic Model)

(A) PCR analysis for hexon (upper panel, indicates presence of virus) and v-myc (center panel, indicates presence of NSCs) in ovarian tumor metastases isolated 2 days post-NSC.CRAd-S-pk7 administration. GAPDH is shown as loading control. (B and C) NSC.CRAd-S-pk7 is effective against orthotopic ovarian cancer. (B) Bioluminescence images acquired on 11 days after tumor injection (post-treatment 1) to visualize tumor burden. (C) Quantitative representation of luminescent flux signal presented as the percent change in tumor flux signal from 5 days after tumor injection (pre-treatment) to 5 days after treatment round 1 (gray bars) and treatment round 2 (black bars). Error bars represent the SD. (D) Average percent change in mouse weight ± SEM for each treatment group. (E) Statistical analysis of clinical observation score pairwise comparisons acquired during treatment and 4 weeks afterward. Maximum daily score reflects the worst toxicity each mouse experienced after scoring for clinical symptoms, and early max score represents the earliest day each mouse reached its maximum daily score.